NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Eli Lilly and Company
Duke University
University of Colorado, Denver
Palleon Pharmaceuticals, Inc.
Duke University
Boehringer Ingelheim
Ottawa Hospital Research Institute
Numab Therapeutics AG
Duke University
Intensity Therapeutics, Inc.
Novartis
NantBioScience, Inc.
Bristol-Myers Squibb
Daiichi Sankyo
Pfizer
GlaxoSmithKline
Kaiser Permanente
Pfizer
Exelixis
Stanford University
Hoffmann-La Roche
Massachusetts General Hospital
Samsung Bioepis Co., Ltd.
Pfizer
CytomX Therapeutics
Novartis
Hoffmann-La Roche
Eisai Inc.
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
Stony Brook University
Tesaro, Inc.
Daiichi Sankyo
Pfizer
Medical University of South Carolina
University of Arkansas
Baylor Breast Care Center
National Institutes of Health Clinical Center (CC)
Pfizer
Pfizer
R-Pharm
National Institutes of Health Clinical Center (CC)
Xoft, Inc.
Baylor Breast Care Center
University of California, San Francisco
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Pfizer
InSightec